Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Proteinuria is one of the major risk factors for renal disease progression in patients with chronic nephropathies. Studies in disease models have helped to delineate mechanisms leading to renal structural damage as a result of persistent dysfunction of the glomerular barrier to proteins, even when the primary immune or non-immune insult to the kidney has ceased. From these preclinical studies, a role for endothelin in proteinuric chronic renal diseases has been suggested, thus providing the rationale for novel therapeutic approaches with endothelin receptor antagonists to maximize renoprotection so far achieved with blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin II receptor antagonism. Trials are needed to explore this potential area of clinical interest.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume10
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Endothelins
Kidney
Research
Angiotensin Receptors
Peptidyl-Dipeptidase A
Renin-Angiotensin System
Chronic Renal Insufficiency
Proteinuria
Disease Progression
Proteins
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

@article{ad7ae4a5a65747668f153f07b94a8084,
title = "Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression",
abstract = "Proteinuria is one of the major risk factors for renal disease progression in patients with chronic nephropathies. Studies in disease models have helped to delineate mechanisms leading to renal structural damage as a result of persistent dysfunction of the glomerular barrier to proteins, even when the primary immune or non-immune insult to the kidney has ceased. From these preclinical studies, a role for endothelin in proteinuric chronic renal diseases has been suggested, thus providing the rationale for novel therapeutic approaches with endothelin receptor antagonists to maximize renoprotection so far achieved with blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin II receptor antagonism. Trials are needed to explore this potential area of clinical interest.",
author = "Ariela Benigni and Norberto Perico and Giuseppe Remuzzi",
year = "2001",
doi = "10.1097/00041552-200101000-00001",
language = "English",
volume = "10",
pages = "1--6",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression

AU - Benigni, Ariela

AU - Perico, Norberto

AU - Remuzzi, Giuseppe

PY - 2001

Y1 - 2001

N2 - Proteinuria is one of the major risk factors for renal disease progression in patients with chronic nephropathies. Studies in disease models have helped to delineate mechanisms leading to renal structural damage as a result of persistent dysfunction of the glomerular barrier to proteins, even when the primary immune or non-immune insult to the kidney has ceased. From these preclinical studies, a role for endothelin in proteinuric chronic renal diseases has been suggested, thus providing the rationale for novel therapeutic approaches with endothelin receptor antagonists to maximize renoprotection so far achieved with blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin II receptor antagonism. Trials are needed to explore this potential area of clinical interest.

AB - Proteinuria is one of the major risk factors for renal disease progression in patients with chronic nephropathies. Studies in disease models have helped to delineate mechanisms leading to renal structural damage as a result of persistent dysfunction of the glomerular barrier to proteins, even when the primary immune or non-immune insult to the kidney has ceased. From these preclinical studies, a role for endothelin in proteinuric chronic renal diseases has been suggested, thus providing the rationale for novel therapeutic approaches with endothelin receptor antagonists to maximize renoprotection so far achieved with blockade of the renin-angiotensin system by angiotensin-converting enzyme inhibition or angiotensin II receptor antagonism. Trials are needed to explore this potential area of clinical interest.

UR - http://www.scopus.com/inward/record.url?scp=0035133085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035133085&partnerID=8YFLogxK

U2 - 10.1097/00041552-200101000-00001

DO - 10.1097/00041552-200101000-00001

M3 - Article

C2 - 11195041

AN - SCOPUS:0035133085

VL - 10

SP - 1

EP - 6

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 1

ER -